Drugs / TKI258
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT01596647 | May 2012 → Jul 2014 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02720926 | Sep 2011 → Jan 2012 | colorectal cancer, gastric cancer | National Cancer Centre, Singapore | Terminated | No outcome recorded |
| Phase 1 | NCT01155713 | Jul 2010 → Nov 2013 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01030055 | Feb 2010 → Jun 2012 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01471548 | Sep 2008 → May 2012 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00715182 | Jul 2008 → Jul 2012 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00669097 | Apr 2008 → Jan 2010 | high grade malignant neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00279773 | Sep 2004 → Oct 2007 | acute myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00243763 | — | plasma cell myeloma | Novartis | Terminated | No outcome recorded |
| Phase 27 trials · 3 missed | ||||||
| Phase 2 | NCT01741116 | Nov 2012 → Dec 2014 | hormone-resistant prostate carcinoma | Korean Cancer Study Group | Completed | No outcome recorded |
| Phase 2 | NCT01576380 | Jun 2012 → Sep 2013 | gastric linitis plastica, scirrhous adenocarcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01379534 | Nov 2011 → Mar 2014 | endometrial cancer | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01417143 | Sep 2011 → Dec 2013 | adenoid cystic carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01058434 | May 2010 → Feb 2013 | refractory plasma cell neoplasm | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00790426 | Mar 2010 → Apr 2012 | urothelial carcinoma | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00958971 | Jul 2009 → Mar 2011 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-04-09 | Allarity Therapeutics | MPI – Oncology Venture exercises option to inlicense Dovitinib a Phase 3 Multi Tyrosine Kinase Inhibitor allarity.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TKI258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01576380 ↗ |
| Known as | dovitinib | “This study investigated the metabolism and excretion of dovitinib (TKI258), a tyrosine kinase inhibitor that inhibits fibroblast, vascular endothelial, and platelet-derived...” PMID 23010851 ↗ Aug 20121“TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule.” NCT01417143 ↗ |
| Action | Inhibit | “multitargeted kinase inhibitor” PMID 23400739 ↗ Jan 2013 |
| Route | Oral | “Dovitinib is an oral multitargeted kinase inhibitor” PMID 23400739 ↗ Jan 2013 |